The stock of NeoGenomics, Inc. (NASDAQ:NEO) hit a new 52-week high and has $10.32 target or 9.00% above today’s $9.47 share price. The 8 months bullish chart indicates low risk for the $763.81M company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $10.32 price target is reached, the company will be worth $68.74 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.64% or $0.06 during the last trading session, hitting $9.47. About 322,140 shares traded hands. NeoGenomics, Inc. (NASDAQ:NEO) has risen 31.42% since April 22, 2016 and is uptrending. It has outperformed by 26.02% the S&P500.
Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on March, 7. They expect $0.02 earnings per share, 0.00% or $0.00 from last year’s $0.02 per share. NEO’s profit will be $1.61M for 118.38 P/E if the $0.02 EPS becomes a reality. After $-0.01 actual earnings per share reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -300.00% EPS growth.
NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage
Out of 8 analysts covering NeoGenomics (NASDAQ:NEO), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. NeoGenomics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, October 26 by TH Capital. Roth Capital reinitiated it with “Buy” rating and $10 target price in Wednesday, May 11 report. The stock has “Buy” rating given by Roth Capital on Thursday, September 3. The firm earned “Outperform” rating on Sunday, September 6 by William Blair. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Overweight” rating by First Analysis on Tuesday, October 4. BTIG Research downgraded NeoGenomics, Inc. (NASDAQ:NEO) on Wednesday, July 27 to “Neutral” rating. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, March 11 by Benchmark. On Wednesday, November 16 the stock rating was downgraded by Axiom Capital to “Sell”.
According to Zacks Investment Research, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.”
Insitutional Activity: The institutional sentiment decreased to 1.25 in 2016 Q2. Its down 0.75, from 2 in 2016Q1. The ratio fall, as 5 funds sold all NeoGenomics, Inc. shares owned while 34 reduced positions. 36 funds bought stakes while 42 increased positions. They now own 57.99 million shares or 3.94% more from 55.79 million shares in 2016Q1.
Tiaa Cref Inv Mngmt Limited holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 163,263 shares. Northern Tru holds 881,140 shares or 0% of its portfolio. Ameriprise Financial Incorporated, a Minnesota-based fund reported 196,473 shares. Ladenburg Thalmann Serv accumulated 0.02% or 142,762 shares. Qs Invsts Ltd, a New York-based fund reported 33 shares. Deutsche Comml Bank Ag holds 336,861 shares or 0% of its portfolio. Nationwide Fund Advsrs has 0% invested in the company for 35,329 shares. First National Bank Trust reported 44,000 shares or 0.31% of all its holdings. Cortina Asset Management Ltd Liability, a Wisconsin-based fund reported 891,445 shares. Gamco Invsts Et Al has 50,000 shares for 0% of their US portfolio. Pnc Ser Gru Inc last reported 387 shares in the company. Wells Fargo Co Mn has 0% invested in the company for 41,953 shares. Next Century Growth Investors Ltd Liability Corp owns 2.56 million shares or 0.96% of their US portfolio. The Illinois-based Rmb Cap Management Llc has invested 0.86% in NeoGenomics, Inc. (NASDAQ:NEO). State Board Of Administration Of Florida Retirement holds 17,810 shares or 0% of its portfolio.
Insider Transactions: Since August 19, 2016, the stock had 0 insider purchases, and 4 insider sales for $4.43 million net activity. On Friday, August 19 the insider ALBITAR MAHER sold $3.05 million.
More important recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Fool.com which released: “Why Neogenomics Inc is Soaring Higher Today” on October 21, 2015, also Marketwatch.com published article titled: “NeoGenomics started at buy with $8 stock price target at Benchmark”, Prnewswire.com published: “NeoGenomics Completes Acquisition of Clarient, Inc.” on December 30, 2015. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) was released by: Prnewswire.com and their article: “NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.” with publication date: October 21, 2015.
NEO Company Profile
NeoGenomics, Inc., incorporated on October 28, 1998, is an operator of a network of cancer-focused genetic testing laboratories. The Firm operates in Laboratory Testing Segment. The Company’s Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Firm has laboratory locations in Ft. Myers and Tampa, Florida; Fresno, Irvine, and West Sacramento, California, and Nashville, Tennessee. The Firm offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues; molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level; Pathology consultation- services provided for clients in which the Company’s pathologists review surgical samples on a consultative basis, and Pharma Services and Clinical Trials-Services supporting pharmaceutical firms in their drug development programs by supporting various clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.